>>Signaling Pathways>> Microbiology & Virology>> Enterovirus>>Pleconaril (VP 63843)

Pleconaril (VP 63843) (Synonyms: VP 63843, Win 63843)

Catalog No.GC32067

Pleconaril(VP 63843)은 이전에 엔테로바이러스 감염 치료에 사용된 캡시드 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Pleconaril (VP 63843) Chemical Structure

Cas No.: 153168-05-9

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$89.00
재고 있음
5mg
US$81.00
재고 있음
10mg
US$119.00
재고 있음
50mg
US$414.00
재고 있음
100mg
US$607.00
재고 있음
200mg
US$836.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pleconaril is a capsid inhibitor used previously to treat enterovirus infections. Pleconaril is effective in inhibiting replication with an IC50 of 50 nM.Target: enterovirusPleconaril is a capsid inhibitor designed to dock within a hydrophobic pocket formed by the capsid proteins VP1, VP3 and VP2. Pleconaril leads to stiffening of the capsid structure,preventing RNA release into the cell. Pleconaril has been used as treatment on a compassionateuse basis in neonates and immunodeficient patients with severe EV infections.

[1]. Benschop KS, et al. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J Gen Virol. 2015 Mar;96(Pt 3):571-9. [2]. Lacroix C, et al. http://www.ncbi.nlm. In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. Virol J. 2015 Jul 14;12:106.

리뷰

Review for Pleconaril (VP 63843)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pleconaril (VP 63843)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.